Clin2
NCT07252661Likely a fitNot yet recruiting

ACC-1898 for advanced solid tumors

Hepatocellular CarcinomaRenal Cell CarcinomaThyroid Carcinoma, MedullaryThyroid Carcinoma Primary DifferentiatedGastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaMelanomaGall Bladder Cancer

Part of Cancer, Digestive system, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.

This trial tests a new pill called ACC-1898 for adults with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and can help shrink or slow tumor growth.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
40 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older with a type of cancer that has spread or come back after standard treatment, or for which there is no standard treatment.
  • You have at least one tumor that can be measured on a scan.
  • You are generally active and able to take care of yourself (ECOG 0 or 1).
  • Side effects from previous treatments have mostly resolved.
  • Your liver, kidneys, and blood counts are working well enough.
  • If you could become pregnant, you must use effective birth control during and for 6 months after treatment; men must use condoms and not donate sperm for 4 months.
  • You can swallow pills and keep them down (no severe nausea, vomiting, or diarrhea).
  • You do not have untreated or unstable brain tumors, uncontrolled infections, or significant heart problems.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07070518Recruiting· Phase 1/Phase 2
Study of GV20-0251 for advanced solid tumors

This trial tests a new study drug, GV20-0251, for people with advanced solid tumors that no longer respond to standard therapies. It aims to see if the drug can shrink tumors or slow their growth.

Beijing, Beijing Municipality
NCT06462183Recruiting· Phase 1
Study of RGT-61159 for Advanced ACC or CRC

This trial tests a new drug called RGT-61159 for adults with adenoid cystic carcinoma or colorectal cancer that has returned or stopped responding to treatment. The goal is to see if the drug is safe and effective in shrinking tumors.

Boston, Massachusetts
NCT06336707Recruiting· Phase 1
HS-20089 combination for advanced solid tumors

This trial tests a new combination treatment called HS-20089 for people with advanced solid tumors. The goal is to see if it is safe and how well it works against cancer that has not responded to other treatments.

Shanghai, Shanghai Municipality
NCT06359860Recruiting· Phase 1/Phase 2
Testing ST-1898 for advanced acral melanoma

This study tests a new oral drug called ST-1898 for people with advanced acral melanoma that has not responded to standard treatments. It aims to see if the drug can shrink or slow the growth of the cancer.

Beijing
NCT07321574Recruiting· Phase 2
Testing ABP1011T for advanced solid tumors

This trial tests an experimental pill called ABP1011T for people with advanced solid tumors that are no longer responding to standard treatments. It is especially focused on small cell lung cancer and other cancers that might be sensitive to this drug. The goal is to see if the pill can shrink tumors or slow their growth.

Luoyang, Henan
NCT07730021Not yet recruiting· Phase 1/Phase 2
Study of ASP388B for Advanced Solid Tumors

This trial tests an investigational drug called ASP388B, either alone or with standard treatments, for people with certain advanced solid tumors that have not responded to usual therapies. The goal is to see if it can shrink tumors or slow their growth.

Hear when a new Hepatocellular Carcinoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.